[go: up one dir, main page]

MY134311A - Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol - Google Patents

Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol

Info

Publication number
MY134311A
MY134311A MYPI20031965A MYPI20031965A MY134311A MY 134311 A MY134311 A MY 134311A MY PI20031965 A MYPI20031965 A MY PI20031965A MY PI20031965 A MYPI20031965 A MY PI20031965A MY 134311 A MY134311 A MY 134311A
Authority
MY
Malaysia
Prior art keywords
methylpentan
methoxyphenyl
dimethylamino
released
hours
Prior art date
Application number
MYPI20031965A
Inventor
Johannes Dr Bartholomaus
Iris Dr Ziegler
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of MY134311A publication Critical patent/MY134311A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

THE INVENTION RELATES TO A PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE OF ACTIVE CONSTITUENT, WHICH CONTAINS 1- DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-OL OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS IN A MATRIX, WITH DELAYED RELEASE OF ACTIVE CONSTITUENT, WHEREIN THE MATRIX CONTAINS 1 TO 80 WT.% OF ONE OR MORE HYDROPHILIC OR HYDROPHOBIC POLYMERS AS PHARMACEUTICALLY ACCEPTABLE MATRIX- FORMING AGENTS AND HAS THE FOLLOWING IN VITRO DISSOLUTION RATE: 3-35 WT.% (REFERRED TO 100 WT.% OF ACTIVE CONSTITUENT) OF 1 DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2- METHYLPENTAN-3-OL RELEASED AFTER 0.5 HOUR, 5-50 WT.% OF 1- DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-OL RELEASED AFTER 1 HOUR, 10-75 WT.% OF 1-DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-OL RELEASED AFTER 2 HOURS, 15-82 WT.% OF 1-DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2- METHYLPENTAN-3-OL RELEASED AFTER 3 HOURS, 30-97 WT.% OF 1- DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-OL RELEASED AFTER 6 HOURS, MORE THAN 50 WT.% OF 1- DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-OL RELEASED AFTER 12 HOURS, MORE THAN 70 WT.% OF 1- DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-OL RELEASED AFTER 18 HOURS, AND MORE THAN 80 WT.% OF 1- DIMETHYLAMINO-3-(3-METHOXYPHENYL)-2-METHYLPENTAN-3-O1 RELEASED AFTER 24 HOURS.
MYPI20031965A 2002-05-29 2003-05-28 Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol MY134311A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10224108A DE10224108A1 (en) 2002-05-29 2002-05-29 1-Dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol containing sustained-release drug

Publications (1)

Publication Number Publication Date
MY134311A true MY134311A (en) 2007-12-31

Family

ID=29557413

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20031965A MY134311A (en) 2002-05-29 2003-05-28 Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol

Country Status (14)

Country Link
EP (1) EP1507519B1 (en)
JP (1) JP5459818B2 (en)
AR (1) AR039900A1 (en)
AT (1) ATE326218T1 (en)
AU (1) AU2003238397A1 (en)
CA (1) CA2488220C (en)
DE (2) DE10224108A1 (en)
DK (1) DK1507519T3 (en)
ES (1) ES2263976T3 (en)
MY (1) MY134311A (en)
PE (1) PE20040529A1 (en)
PL (1) PL218397B1 (en)
PT (1) PT1507519E (en)
WO (1) WO2003099267A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH06172161A (en) * 1992-12-10 1994-06-21 Shin Etsu Chem Co Ltd Sustained release tablet
DE4329794C2 (en) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadol salt-containing drugs with delayed release
DE4426245A1 (en) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
DE10059412A1 (en) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Use of 1-phenyl-3-dimethylamino-propane compounds for the treatment of urinary incontinence
DE10146275A1 (en) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Combination of selected opioids with muscarinic antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
PT1507519E (en) 2006-08-31
AR039900A1 (en) 2005-03-09
AU2003238397A1 (en) 2003-12-12
ATE326218T1 (en) 2006-06-15
CA2488220A1 (en) 2003-12-04
PL374186A1 (en) 2005-10-03
CA2488220C (en) 2011-02-01
DK1507519T3 (en) 2006-08-28
DE10224108A1 (en) 2004-01-29
JP2005534640A (en) 2005-11-17
JP5459818B2 (en) 2014-04-02
PL218397B1 (en) 2014-11-28
EP1507519A1 (en) 2005-02-23
PE20040529A1 (en) 2004-08-24
ES2263976T3 (en) 2006-12-16
DE50303372D1 (en) 2006-06-22
WO2003099267A1 (en) 2003-12-04
EP1507519B1 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
MY127797A (en) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
WO2008107149A3 (en) Pharmaceutical form with impeded abuse
WO2007048219A3 (en) Sustained drug release composition
EP2266542A3 (en) Controlled release nanoparticulate compositions
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
ATE396712T1 (en) PHARMACEUTICAL PREPARATION FOR MODIFIED RELEASE
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
BR0107874A (en) Pharmaceutical implant for controllably releasing a drug, method for controllably releasing a drug in an individual, and method for preparing the implant
ES2194732T3 (en) ORAL PHARMACEUTICAL COMPOSITIONS OF CONTROLLED LIBERATION OF MESALAZINE.
HUP0003405A2 (en) Controlled release of drugs delivered by sublingual or buccal adminisration
MY148475A (en) Controlled release preparations comprising tramadol and topiramate
MX2009004439A (en) Ibuprofen composition.
WO2006056711A3 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2001047498A3 (en) Hydrogel-driven layered drug dosage form comprising sertraline
PE20001414A1 (en) PROCEDURE FOR PREPARING BALLOONS CONTAINING 50% BY WEIGHT OR MORE OF A PHARMACEUTICAL SUBSTANCE OF WATER SOLUBILITY
ATE476997T1 (en) COMPOSITION AND DOSAGE FORM COMPRISING A SOLID OR SEMI-SOLID MATRIX
WO2005009329A3 (en) Medicament containing 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol with delayed release of active ingredients
BR0311327A (en) Oxcarbazepine-containing pharmaceutical composition with sustained release of an active ingredient
WO2002034267A8 (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
WO2006107593A3 (en) Matrix-based pulse release pharmaceutical formulation
RS20060252A (en) Pelletes containing venlafaxine hydrochloride
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
WO2007031326A3 (en) 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation